| Description |
1 online resource (viii, 161 pages) : color illustrations |
| Contents |
1. BCR-ABL as a molecular target / Michael Deininger -- 2. Allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia / Mukta Arora and Mary M. Horowitz -- 3. Where Are We Today with Imatinib Therapy? / John M. Goldman -- 4. Monitoring chronic myeloid leukemia in 2006 / Nicola Hurst, Timothy P. Hughes, and Susan Branford -- 5. Dasatinib : a dual ABL and SRC inhibitor / Alfonso Quintás-Cardama, Hagop Kantarjian, and Jorge Cortes -- 6. Nilotinib (AMN107) for the treatment of chronic myelogenous leukemia / Elias Jabbour [and others] -- 7. Resistance to imatinib / Justus Duyster and Nikolas von Bubnoff -- 8. Immunotherapy of chronic myeloid leukemia / Monica Bocchia and Francesco Lauria -- 9. Molecular targets other than Bcr-Abl : how to incorporate them into the CML therapy? / Junia V. Melo and David J. Barnes -- 10. Blastic transformation of chronic myelogenous leukemia : does BCR-ABL orchestrate disease progression? / Bruno Calabretta and Danilo Perrotti -- 11. Early intensification of therapy : the role of high-dose imatinib and imatinib-based combinations / François Guilhot [and others] |
| Summary |
Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve p |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Chronic myeloid leukemia.
|
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- therapy
|
|
Antineoplastic Agents -- therapeutic use
|
|
Fusion Proteins, bcr-abl -- antagonists & inhibitors
|
|
Hematopoietic Stem Cell Transplantation
|
|
Immunotherapy -- methods
|
|
Protein Kinase Inhibitors -- therapeutic use
|
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
PHILOSOPHY -- Logic.
|
|
Chronic myeloid leukemia
|
| Form |
Electronic book
|
| Author |
Cortés F., Jorge E. (Jorge Eduardo Cortés Franco)
|
|
Deininger, Michael.
|
| ISBN |
9780849379567 |
|
0849379563 |
|
1280866616 |
|
9781280866616 |
|
9780429164545 |
|
0429164548 |
|
